Dabigatran Etexilate Uses, Dosage, Side Effects and Interactions
Pradaxa
Pradaxa was the first dabigatran etexilate product the FDA approved, in October 2010. A generic is listed for its capsules, but not for its oral pellets.
Dabigatran etexilate is a blood thinner (direct thrombin inhibitor) used to lower stroke risk in non-valvular atrial fibrillation and to prevent or treat dangerous blood clots in the legs and lungs, in adults and in children.
Quick links
Ask Anything About Dabigatran EtexilateType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Dabigatran Etexilate in Short
- Drug class Direct Thrombin Inhibitor How the FDA classifies it
What it treatsDabigatran etexilate is used to prevent and treat blood clots. Which uses apply depends on the product and your age. Capsules (adults): lower the risk of stroke and systemic embolism (a clot traveling to other parts of the body) in non-valvular atrial fibrillation; treat deep venous thrombosis (DVT) and pulmonary…
- How you get it Prescription only
- Comes asCapsule and oral pelletsAvailable strengths
Capsule (by mouth)
- 75 mg
- 110 mg
- 150 mg
Oral pellets (by mouth)
- 20 mg
- 30 mg
- 40 mg
See forms and strengths+ 3 more strengthsShow fewer strengths
Oral pellets (by mouth)
- 50 mg
- 110 mg
- 150 mg
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Dabigatran etexilate mesylate (capsule); Pradaxa (capsule)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- What pharmacies pay
- Generic$0.72 to $0.87 a capsule
- Pradaxa (brand)$3.16 to $3.18 a capsule
- Oral pellets: no national price found
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Dabigatran etexilate (Pradaxa) is a blood thinner that blocks thrombin, a clotting protein, to lower stroke risk in atrial fibrillation not caused by a valve problem and to treat and prevent leg and lung clots; on the market since about 2010, with generics approved, it is a familiar warfarin alternative that skips routine clotting blood tests. Most people tolerate it well, though indigestion and upper stomach pain are common (food often helps) and bruising comes more easily. Bleeding is the main risk, and the boxed warning adds that stopping early can bring on a clot or stroke, so never stop it on your own.
Key Takeaways From the HelloPharmacist Team
- Swallow the capsules whole, usually twice a day, and never open, chew or break them, since that raises how much drug you absorb.
- Get help right away for bleeding that will not stop, black or bloody stools, vomiting blood, or sudden unusual weakness.
- Check with your pharmacist before taking ibuprofen, naproxen or aspirin, which add to bleeding risk; acetaminophen is usually the safer pain choice.
- Tell every doctor and dentist you take it before any procedure, and report leg numbness or weakness promptly after a spinal or epidural.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Dabigatran Etexilate.
Stopping dabigatran too early can raise your risk of a dangerous blood clot or stroke. Do not stop unless your doctor tells you to. If it must be stopped for a reason other than bleeding or finishing treatment, your doctor may cover you with another blood thinner.
Spinal or epidural bleeding: if you have an epidural, spinal anesthesia or spinal puncture while on this medicine, a blood clot can press on the spinal cord and cause long-term or permanent paralysis. Risk is higher with an indwelling epidural catheter, NSAIDs, platelet inhibitors or other blood thinners, past repeated spinal punctures, or spinal deformity or surgery. Report back pain, numbness, tingling, leg weakness, or bowel or bladder problems right away.
Patient Information Guide for Dabigatran Etexilate
What It’s Used For
Dabigatran etexilate is a blood thinner used to prevent and treat clots.
- Capsules, adults: lower stroke and systemic embolism risk in non-valvular atrial fibrillation.
- Capsules, adults: treat DVT and PE after 5-10 days of an injected or IV blood thinner.
- Capsules, adults: lower the risk of DVT and PE coming back.
- Capsules, adults: prevent DVT and PE after hip replacement surgery.
- Pradaxa capsules and some other dabigatran capsules, ages 8 to under 18: treat VTE and lower the risk of recurrence.
- Pradaxa oral pellets, ages 3 months to under 12: treat VTE and lower the risk of recurrence.
How It Works
Dabigatran is a direct thrombin inhibitor. Thrombin turns fibrinogen into fibrin, which builds clots. By blocking thrombin, including thrombin stuck in a clot, dabigatran helps prevent clots from forming. It also reduces thrombin-driven platelet clumping.
Drug Class
Drug Class
- Direct Thrombin Inhibitor
From Dabigatran Etexilate’s FDA label.
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Direct Thrombin Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
What It Does in the Body
Physiologic effect (PE)None listed for Dabigatran Etexilate in the FDA’s index.
From our Patient Information GuideDabigatran is a direct thrombin inhibitor. Thrombin turns fibrinogen into fibrin, which builds clots. By blocking thrombin, including thrombin stuck in a clot, dabigatran helps prevent clots from forming. Read How Dabigatran Etexilate Works
A change it makes in how the body works.
Drug Family
WHO ATC classification- Direct thrombin inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The drug class comes from Dabigatran Etexilate’s FDA label. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification, from the U.S. National Library of Medicine’s RxClass. Reference only, not medical advice.
Dosage
Capsules are taken by mouth, with or without food, and swallowed whole. Most uses are twice daily; hip replacement prevention is once daily.
Pradaxa oral pellets are twice daily for children who can swallow soft food.
- Do not swap forms milligram for milligram.
- Do not combine forms to make up a dose.
- Your doctor may pause it before surgery and restart it promptly.
Follow your prescriber and label.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Dabigatran Etexilate Capsules
Lowering stroke risk in atrial fibrillation not caused by a heart valve problem
Adults Usual dose 75 mg twice a day
- Reduce dosage to 75 mg twice daily
Good to know
CrCl < 30 mL/min with P-gp inhibitors: avoid co-administration
CrCl means creatinine clearance, a measure of how well the kidneys work.
Adults with kidney function (CrCl) above 30 mL/min Usual dose 150 mg twice a day
CrCl means creatinine clearance, a measure of how well the kidneys work.
Adults with severe kidney problems (CrCl 15 to 30 mL/min) Usual dose 75 mg twice a day
CrCl means creatinine clearance, a measure of how well the kidneys work.
Treating blood clots in the leg or lung (DVT and PE)
For adults with kidney function (CrCl) above 30 mL/min
Usual dose 150 mg twice a day
- 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation
Good to know
CrCl < 50 mL/min with P-gp inhibitors: avoid co-administration
DVT stands for deep venous thrombosis.
PE stands for pulmonary embolism.
CrCl means creatinine clearance, a measure of how well the kidneys work.
Lowering the chance of blood clots in the leg or lung coming back (DVT and PE)
For adults with kidney function (CrCl) above 30 mL/min
Usual dose 150 mg twice a day
- 150 mg orally, twice daily after previous treatment
Good to know
CrCl < 50 mL/min with P-gp inhibitors: avoid co-administration
DVT stands for deep venous thrombosis.
PE stands for pulmonary embolism.
CrCl means creatinine clearance, a measure of how well the kidneys work.
Preventing blood clots in the leg or lung after hip replacement surgery
For adults with kidney function (CrCl) above 30 mL/min
Starting dose 110 mg once on the first day
Usual dose 220 mg once a day
Step by step
- 110 mg for first day, then 220 mg once daily
- First dose 1-4 hours after surgery and after hemostasis, then 220 mg once daily for 28-35 days
Good to know
CrCl <50 mL/min with P-gp inhibitors: avoid co-administration
CrCl means creatinine clearance, a measure of how well the kidneys work.
Pradaxa
Treating or preventing return of blood clots (VTE) in children
Babies 3 to less than 6 months old, 3 kg to less than 4 kg Usual dose 30 mg twice a day
- 30 mg twice daily (one 30 mg packet twice daily)
Babies 3 to less than 10 months old, 4 kg to less than 5 kg Usual dose 40 mg twice a day
- 40 mg twice daily (one 40 mg packet twice daily)
Children 2 to less than 12 years old, 11 kg to less than 13 kg Usual dose 110 mg twice a day
- 110 mg twice daily (one 110 mg packet twice daily)
Side Effects
The most common effects are stomach problems and bleeding.
Common side effects
- Bleeding (including bruising or nosebleeds)
- Indigestion or upper stomach pain
- Nausea
- Diarrhea
- Stomach irritation or gastritis-like symptoms (such as reflux)
When to get medical help
- Signs of serious bleeding, such as a big drop in blood pressure, unusual weakness or blood loss. Get help right away.
- Back pain, numbness, tingling or weakness in the legs, or bowel or bladder problems, especially after a spinal or epidural procedure. Report immediately.
- Signs of a severe allergic reaction, such as hives, swelling or trouble breathing.
- Bleeding in the stomach or gut, or bleeding that will not stop.
- Any new stroke or clot symptoms if you have stopped the medicine.
Warnings and Precautions
- Bleeding: serious and sometimes fatal. Higher with kidney impairment, older age, and drugs that affect clotting.
- Stopping early: raises clot and stroke risk.
- Spinal or epidural hematoma: can cause permanent paralysis after spinal procedures.
- Mechanical heart valves: must not use it.
- Bioprosthetic valves and triple-positive antiphospholipid syndrome: not recommended.
Interactions
Some drugs change how much dabigatran is in your body or add to bleeding risk.
- Rifampin (a P-gp inducer): lowers dabigatran levels, so generally avoid.
- Dronedarone and systemic ketoconazole (P-gp inhibitors): raise levels and may need a dose change or avoidance.
- Antiplatelet drugs, heparin, clot-dissolving drugs and long-term NSAIDs: add to bleeding risk.
Interactions Listed in the FDA-Approved Label
From the Dabigatran Etexilate prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
P-gp inducers For example: rifampinWhat happensReduces exposure to dabigatran.What to doShould generally be avoided.
-
P-gp inhibitors dronedarone or systemic ketoconazole (adults with CrCl 30-50 mL/min, atrial fibrillation)What happensExpected to produce dabigatran exposure similar to that seen in severe renal impairment.What to doReduce the dosage to 75 mg twice daily.
-
P-gp inhibitors in patients with CrCl < 50 mL/min (DVT/PE treatment, recurrence, or hip surgery prophylaxis) or CrCl 15-30 mL/min (atrial fibrillation)What happensIncreased dabigatran exposure compared with either factor alone.What to doAvoid concomitant use.
-
Verapamil, amiodarone, quinidine, clarithromycin, ticagrelorWhat happensUse of these P-gp inhibitors does not require a dosage adjustment of dabigatran etexilate capsules.What to doResults should not be extrapolated to other P-gp inhibitors.
-
Proton pump inhibitors, H2 antagonists, digoxinWhat happensDid not appreciably change the trough concentration of dabigatran.
Read the label’s full interactions text
7 DRUG INTERACTIONS • P-gp inducers: Avoid coadministration with dabigatran etexilate capsules • P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid • P-gp inhibitors in adult patients with CrCl < 30 mL/min: Not recommended 7.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate capsules with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dosage of dabigatran etexilate capsules to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dosage adjustment of dabigatran etexilate capsules. These results should not be extrapolated to other P-gp inhibitors. The concomitant use of dabigatran etexilate capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use with active bleeding, a mechanical heart valve, or a past serious allergy to dabigatran.
- Tell your doctor about kidney disease, since it raises drug levels.
- Older adults have higher bleeding risk.
- Pregnancy: data are limited; discuss with your doctor.
- Breastfeeding is not recommended.
- Children not studied with eGFR below 50 should avoid it.
Overdose
Too much can cause bleeding. The treatment is to stop the drug, investigate the bleeding source and give supportive care. In adults, a reversal agent (idarucizumab) is available, and hemodialysis can remove some dabigatran.
Half-Life and How Your Body Processes It
The drug is absorbed as dabigatran etexilate and converted to active dabigatran. Only about 3% to 7% is absorbed. Food delays peak levels by about 2 hours but does not change the amount absorbed. It is cleared mainly through the kidneys, with a half-life of about 12 to 17 hours in healthy adults. Kidney impairment raises exposure and lengthens the half-life.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Store in the original package to protect from moisture.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Dabigatran Etexilate: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Dabigatran Etexilate — the kind of thing our pharmacy team would talk through with you at the counter.
Can I stop taking dabigatran suddenly?
Should I take dabigatran with food?
What side effects should I expect?
What medicines should I avoid with dabigatran?
Is dabigatran safe if I'm pregnant or breastfeeding?
What should I tell my doctor before surgery or a spinal procedure?
Is dabigatran etexilate available over the counter?
When was dabigatran etexilate first available?
Who makes dabigatran etexilate?
What is the brand name of dabigatran etexilate?
What is the generic name of Pradaxa?
What drug class is dabigatran etexilate?
Is there a generic version of dabigatran etexilate?
What strengths does dabigatran etexilate come in?
How much does dabigatran etexilate cost?
Is there a dabigatran etexilate shortage?
Where can I read the dabigatran etexilate prescribing information (package insert)?
Can you crush dabigatran etexilate?
Is dabigatran etexilate gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Dabigatran Etexilate
Skip the scrolling. Ask in your own words and get an answer from Dabigatran Etexilate’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Dabigatran Etexilate’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Dabigatran Etexilate on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Dabigatran Etexilate Forms and Strengths (How It Comes)
Dabigatran Etexilate comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Dabigatran Etexilate inactive ingredients by manufacturer.
Capsule
How this form is used
- Dabigatran etexilate capsules are used in adults for stroke prevention in non-valvular atrial fibrillation, DVT and PE treatment and recurrence prevention, and prevention after hip replacement.
- Pradaxa capsules are also labeled for VTE treatment and recurrence prevention in children 8 to under 18.
- Pradaxa capsules and dabigatran capsules can be taken with or without food.
- Dabigatran capsules should not be broken, chewed or opened.
- Pradaxa capsules are not substitutable milligram for milligram with other dabigatran forms.
Oral pellets
How this form is used
- Pradaxa oral pellets treat VTE in children 3 months to under 12 after at least 5 days of an injected or IV blood thinner.
- Pradaxa oral pellets lower the risk of VTE coming back in children 3 months to under 12.
- Pradaxa oral pellets can be used once a child can swallow soft food.
- Pradaxa oral pellets are given twice daily with a dose based on age and weight.
- Pradaxa oral pellets are not swapped milligram for milligram with capsules, and forms should not be combined.
Dabigatran Etexilate on the U.S. Market: Products, Makers and Brands
How Dabigatran Etexilate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
17 companies list 51 Dabigatran Etexilate product records with the FDA, mostly as capsule, oral pellets; the earliest marketing or approval year on record is 2010. The one brand name in the directory today is Pradaxa; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (24) · Pellet (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Dabigatran Etexilate Is Used (Medicaid Data)
How many Dabigatran Etexilate prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Dabigatran Etexilate prescribed? Of the 1,682 medications we measure, Dabigatran Etexilate ranks #704 by Medicaid prescriptions — more than 58% of them.
Utilization by Dabigatran Etexilate product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
dabigatran etexilate 150 MG Oral Capsule Most dispensed
11 of 35 listed NDCs had Medicaid claims. RxNorm 1037045
dabigatran etexilate 75 MG Oral Capsule
4 of 30 listed NDCs had Medicaid claims. RxNorm 1037179
dabigatran etexilate 110 MG Oral Capsule
5 of 19 listed NDCs had Medicaid claims. RxNorm 1723476
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 20 of the 84 listed Dabigatran Etexilate NDCs had Medicaid claims.
Compare Dabigatran Etexilate Products
A representative set of FDA-listed product records for Dabigatran Etexilate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 75 mg | Oral | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 150 mg | Oral | A-S Medication Solutions × 3 listings | ANDA | View NDC → |
| 75 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 110 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 150 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 75 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 110 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 150 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 75 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 150 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 75 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 110 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 150 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 75 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 110 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 150 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 75 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 110 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 150 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 75 mg | Oral | AvKARE | ANDA | View NDC → |
| 150 mg | Oral | AvKARE | ANDA | View NDC → |
| 150 mg | Oral | AvPAK | ANDA | View NDC → |
| 75 mg | Oral | Boehringer Ingelheim Pharmaceuticals Inc. | NDA | View NDC → |
| 110 mg | Oral | Boehringer Ingelheim Pharmaceuticals Inc. | NDA | View NDC → |
| 150 mg | Oral | Boehringer Ingelheim Pharmaceuticals Inc. | NDA | View NDC → |
| 75 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 110 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 75 mg | Oral | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| 110 mg | Oral | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| 150 mg | Oral | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| 75 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 110 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 150 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 75 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 150 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 150 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 75 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 110 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 150 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 75 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 150 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 💊Oral pellets | ||||
| 20 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 30 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 40 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 50 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 110 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 150 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
Showing 51 of 51 products — FDA National Drug Code Directory. See every product, package size and price: browse all 51 Dabigatran Etexilate NDCs →
Dabigatran Etexilate Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dabigatran Etexilate — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dabigatran Etexilate in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Dabigatran Etexilate FDA Approval History
How Dabigatran Etexilate went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Dabigatran Etexilate Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 4 Dabigatran Etexilate recalls since July 2021, covering 9 product listings. All of them are still ongoing or began in the last six months. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICAL… Lots: Lot: 25141586, Exp. April 30, 2027. FDA record D-0739-2026 →
- Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS… Lots: Lot: 25141585, Exp. April 30, 2027. FDA record D-0738-2026 →
- Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICA… Lots: Lot: 25141583, Exp. April 30, 2027. FDA record D-0737-2026 →
- Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-725… Lots: Lot: 25141584, Exp 4/30/2027. FDA record D-0736-2026 →
- Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-725… Lots: Lot: 25141707, Exp 4/30/2027. FDA record D-0735-2026 →
- Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60 Lots: Lot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026; FDA record D-0130-2025 →
- Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60 Lots: Lot #: 24142328, 24142329, 24142330, Exp. Date May 31, 2026. FDA record D-0129-2025 →
- Dabigatran Etexilate 150mg Capsules, 150 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC 67877… Lots: Lot #s: 22142448, 22142449, 22142450, Exp 5/2024; 22143845, Exp 7/2024. FDA record D-0534-2023 →
- Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-6… Lots: Lot #s: 22142462, 22142463, 22142464, Exp 5/2024; 22143000, 22143001, 22143002, Exp 6/2024. FDA record D-0533-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Dabigatran Etexilate in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 9
- Forms in current FDA listings
- 2 of 2
RxCUI 1037042 RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Dabigatran Etexilate Supply and Shortage Status
Whether Dabigatran Etexilate is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Dabigatran Etexilate Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Dabigatran Etexilate: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
No national price was found for Dabigatran Etexilate oral pellets, so the prices below are for the capsules only.
How the Pharmacy Price Has Changed
Pick the generic or the brand and a strength to see how its price has changed since Nov 2023.
At this strength, Pradaxa costs pharmacies $3.18 per capsule.
For the generic 75 mg capsule, pharmacies paid an average of $0.717 per capsule as of Nov 18, 2026, down 35% from $1.11 a year earlier. At this strength, Pradaxa costs pharmacies $3.18 per capsule.
- What pharmacies pay now
- $0.717
- per capsule, as of Nov 18, 2026
- Last 4 weeks
- Up 0.3%
- from $0.715 on Oct 21, 2026
- Last 12 months
- Down 35%
- from $1.11 on Nov 19, 2025
- Lowest and highest since Aug 2024
- $0.715 to $2.19
- per capsule
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $0.717 |
| Oct 2026 | $0.715 |
| Sep 2026 | $0.750 |
| Aug 2026 | $0.843 |
| Jul 2026 | $0.899 |
| Jun 2026 | $0.898 |
| May 2026 | $0.870 |
| Apr 2026 | $0.848 |
| Mar 2026 | $0.942 |
| Feb 2026 | $1.01 |
| Jan 2026 | $1.05 |
| Dec 2025 | $1.09 |
| Nov 2025 | $1.11 |
| Oct 2025 | $1.13 |
| Sep 2025 | $1.10 |
| Aug 2025 | $1.17 |
| Jul 2025 | $1.31 |
| Jun 2025 | $1.47 |
| May 2025 | $1.52 |
| Apr 2025 | $1.69 |
| Mar 2025 | $1.77 |
| Feb 2025 | $1.86 |
| Jan 2025 | $1.94 |
| Dec 2024 | $2.03 |
| Nov 2024 | $2.19 |
| Oct 2024 | $2.17 |
| Sep 2024 | $2.09 |
| Aug 2024 | $2.08 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Capsule · Oral | 75 mg | Generic | $0.717 per capsule | NDC details & price history |
| Capsule · Oral | 75 mg | Pradaxa (brand) | $3.18 per capsule | NDC details & price history |
| Capsule · Oral | 110 mg | Generic | $0.869 per capsule | NDC details & price history |
| Capsule · Oral | 110 mg | Pradaxa (brand) | $3.17 per capsule | NDC details & price history |
| Capsule · Oral | 150 mg | Generic | $0.773 per capsule | NDC details & price history |
| Capsule · Oral | 150 mg | Pradaxa (brand) | $3.16 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Dabigatran Etexilate Brand Names
Dabigatran Etexilate has one brand name on record: Pradaxa. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Dabigatran Etexilate: Manufacturers and Labelers
17 companies list Dabigatran Etexilate products with the FDA. By number of product records, the largest are Boehringer Ingelheim Pharmaceuticals, Inc., A-S Medication Solutions, Alembic Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Dabigatran Etexilate Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Boehringer Ingelheim Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →